Supernus Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Supernus Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues | 147,000 | 91,000 | |||||||||||||||||||||||||||||||||||||||||||||
| net product sales | 157,995,000 | 141,988,000 | 166,395,000 | 170,302,000 | 162,538,000 | 138,461,000 | 156,018,000 | 149,004,000 | 128,336,000 | 140,575,000 | 163,785,000 | 172,724,000 | 165,459,000 | 147,464,000 | 154,963,000 | 145,532,000 | 138,628,000 | 128,381,000 | 140,743,000 | 152,133,000 | 123,984,000 | 92,490,000 | 97,909,000 | 100,034,000 | 102,358,000 | 83,099,000 | 100,227,000 | 97,030,000 | 89,120,000 | 78,066,000 | 73,328,000 | 56,369,000 | 55,618,000 | 50,335,000 | 43,025,000 | 38,551,000 | 34,266,000 | 28,097,000 | 22,452,000 | 27,609,000 | 8,995,000 | 1,130,000 | 154,000 | ||||
| royalty, licensing and other revenues | 7,458,000 | 7,836,000 | 7,764,000 | 5,387,000 | 5,787,000 | ||||||||||||||||||||||||||||||||||||||||||
| total revenues | 165,453,000 | 149,824,000 | 174,159,000 | 175,689,000 | 168,325,000 | 143,644,000 | 164,314,000 | 153,880,000 | 135,563,000 | 153,764,000 | 167,328,000 | 177,353,000 | 170,051,000 | 152,506,000 | 159,050,000 | 148,464,000 | 141,329,000 | 130,932,000 | 143,557,000 | 155,135,000 | 126,729,000 | 94,976,000 | 100,446,000 | 102,140,000 | 104,695,000 | 85,474,000 | 91,000 | 208,000 | |||||||||||||||||||
| costs and expenses | |||||||||||||||||||||||||||||||||||||||||||||||
| cost of goods sold | 16,827,000 | 15,763,000 | 26,098,000 | 17,583,000 | 17,916,000 | 16,309,000 | 19,627,000 | 19,601,000 | 21,091,000 | 23,460,000 | 22,954,000 | 25,878,000 | 20,457,000 | 17,932,000 | 16,994,000 | 18,085,000 | 25,028,000 | 14,954,000 | 18,533,000 | 21,388,000 | 8,386,000 | 4,152,000 | 4,113,000 | 4,819,000 | |||||||||||||||||||||||
| research and development | 22,115,000 | 26,927,000 | 28,647,000 | 29,036,000 | 26,183,000 | 24,930,000 | 23,347,000 | 22,655,000 | 24,379,000 | 21,212,000 | 17,774,000 | 19,554,000 | 16,385,000 | 20,839,000 | 21,078,000 | 19,654,000 | 15,455,000 | 34,280,000 | 17,938,000 | 16,839,000 | 22,247,000 | 18,937,000 | 19,792,000 | 16,943,000 | 16,970,000 | 15,394,000 | 20,422,000 | 20,038,000 | 18,908,000 | 12,980,000 | 10,823,000 | 9,601,000 | 7,868,000 | 11,109,000 | 10,562,000 | 9,129,000 | 6,878,000 | 3,683,000 | 4,657,000 | 4,677,000 | 4,482,000 | 3,779,000 | 3,542,000 | 4,522,000 | 8,306,000 | 4,703,000 | 5,358,000 |
| selling, general and administrative | 93,551,000 | 89,944,000 | 79,409,000 | 69,753,000 | 85,904,000 | 86,516,000 | 81,282,000 | 82,700,000 | 86,782,000 | 85,597,000 | 73,972,000 | 112,314,000 | 100,476,000 | 90,459,000 | 101,735,000 | 72,032,000 | 69,535,000 | 61,457,000 | 56,300,000 | 54,660,000 | 48,103,000 | 42,875,000 | 35,725,000 | 40,649,000 | 41,083,000 | 40,968,000 | 40,892,000 | 40,097,000 | 36,849,000 | 40,825,000 | 35,078,000 | 28,238,000 | 25,675,000 | 26,121,000 | 25,160,000 | 22,900,000 | 23,336,000 | 19,402,000 | 17,343,000 | 19,581,000 | 17,527,000 | 14,620,000 | 12,214,000 | 13,533,000 | 4,075,000 | 4,645,000 | |
| amortization of intangible assets | 20,819,000 | 19,786,000 | 18,244,000 | 19,488,000 | 20,108,000 | 20,137,000 | 21,069,000 | 21,242,000 | 20,108,000 | 19,966,000 | 20,698,000 | 20,644,000 | 20,644,000 | 20,644,000 | 12,025,000 | 6,009,000 | 5,948,000 | 6,007,000 | 5,888,000 | 6,108,000 | 2,445,000 | ||||||||||||||||||||||||||
| contingent consideration gain | 7,660,000 | 356,000 | -1,016,000 | -1,095,000 | -8,750,000 | ||||||||||||||||||||||||||||||||||||||||||
| total costs and expenses | 153,312,000 | 160,080,000 | 152,754,000 | 134,844,000 | 145,756,000 | 146,797,000 | 165,310,000 | 145,742,000 | 153,150,000 | 148,588,000 | 132,994,000 | 178,876,000 | 158,705,000 | 150,539,000 | 152,952,000 | 115,860,000 | 107,216,000 | 117,718,000 | 100,559,000 | 98,995,000 | 81,181,000 | 65,964,000 | 59,630,000 | 62,411,000 | 62,097,000 | 60,046,000 | 65,521,000 | 63,818,000 | 59,035,000 | 58,056,000 | 49,762,000 | 40,788,000 | 36,971,000 | 39,981,000 | 37,757,000 | 34,277,000 | 31,976,000 | 24,703,000 | 23,321,000 | 25,919,000 | 22,503,000 | 18,432,000 | 15,760,000 | 18,055,000 | 12,381,000 | 9,348,000 | 8,086,000 |
| operating earnings | 12,141,000 | 21,405,000 | 40,845,000 | 22,569,000 | -3,153,000 | -996,000 | 8,138,000 | -17,587,000 | 5,176,000 | 34,334,000 | -1,523,000 | 11,346,000 | 1,967,000 | 6,098,000 | 32,604,000 | 34,113,000 | 13,214,000 | 42,998,000 | 56,140,000 | 45,548,000 | 29,012,000 | 40,816,000 | 39,729,000 | 42,598,000 | 25,428,000 | 37,475,000 | 35,720,000 | 31,394,000 | |||||||||||||||||||
| other income | 731,250 | -603,000 | 3,326,000 | 2,000 | 5,000 | 25,000 | 2,000 | 6,000 | 169,000 | 141,000 | |||||||||||||||||||||||||||||||||||||
| interest and other income | 4,528,000 | 4,425,000 | 4,977,000 | 4,098,000 | 3,733,000 | 3,396,000 | 1,986,000 | 1,751,000 | 1,370,000 | 5,346,000 | 2,400,000 | 2,803,000 | 1,788,000 | 14,698,000 | 1,887,000 | 2,281,000 | 2,589,000 | 3,812,000 | |||||||||||||||||||||||||||||
| total other income | 4,528,000 | 4,425,000 | 4,977,000 | 4,098,000 | 3,733,000 | 3,396,000 | 1,986,000 | 1,751,000 | 460,000 | 3,841,000 | 806,000 | 1,079,000 | -22,000 | 12,756,000 | -4,047,000 | -3,644,000 | -2,878,000 | -2,285,000 | -3,305,000 | -3,429,000 | 1,662,000 | 22,000 | 568,000 | 358,000 | 292,000 | -6,921,000 | -11,878,000 | ||||||||||||||||||||
| earnings before income taxes | 16,669,000 | -5,831,000 | 26,382,000 | 44,943,000 | 26,302,000 | 243,000 | 990,000 | 9,889,000 | -17,127,000 | 9,017,000 | 35,140,000 | -444,000 | 11,324,000 | 14,723,000 | 2,051,000 | 28,960,000 | 31,235,000 | 10,929,000 | 39,693,000 | 52,711,000 | 47,210,000 | 29,034,000 | 40,912,000 | 39,590,000 | 42,746,000 | 24,239,000 | 36,371,000 | 33,856,000 | 31,182,000 | 22,910,000 | 26,425,000 | 16,223,000 | 19,136,000 | 10,732,000 | 5,185,000 | 4,280,000 | 2,667,000 | 979,000 | |||||||||
| income tax benefit | -5,830,000 | 6,386,000 | 119,000 | 409,500 | 25,865,000 | -16,296,000 | -7,931,000 | 6,949,000 | |||||||||||||||||||||||||||||||||||||||
| net earnings | 22,499,000 | -11,827,000 | 15,328,000 | 38,497,000 | 19,916,000 | 124,000 | 1,175,000 | -15,976,000 | -831,000 | 16,948,000 | 25,481,000 | 1,749,000 | 7,865,000 | 25,616,000 | 2,442,000 | 21,562,000 | 23,726,000 | 5,694,000 | 30,768,000 | 39,997,000 | 34,667,000 | 21,518,000 | 33,129,000 | 28,860,000 | 32,727,000 | 18,340,000 | 28,011,000 | 30,737,000 | 26,352,000 | ||||||||||||||||||
| earnings per share | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 0.4 | -0.21 | 0.28 | 0.7 | 0.36 | 0 | 0.02 | -0.29 | -0.02 | 0.31 | 0.47 | 0.03 | 0.15 | 0.48 | 0.05 | 0.41 | 0.45 | 0.11 | 0.58 | 0.76 | 0.66 | 0.41 | 0.63 | 0.55 | 0.62 | 0.35 | 0.54 | 0.59 | 0.51 | 0.31 | 0.34 | 0.21 | |||||||||||||||
| diluted | 0.4 | -0.21 | 0.27 | 0.69 | 0.36 | 0 | 0.02 | -0.29 | -0.02 | 0.29 | 0.42 | 0.03 | 0.14 | 0.43 | 0.04 | 0.4 | 0.43 | 0.11 | 0.57 | 0.74 | 0.65 | 0.4 | 0.62 | 0.54 | 0.61 | 0.34 | 0.52 | 0.57 | 0.49 | 0.29 | 0.32 | 0.19 | |||||||||||||||
| weighted-average shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 56,024,771 | 55,864,692 | 55,100,063 | 55,149,760 | 54,978,781 | 54,801,748 | 54,536,281 | 54,608,963 | 54,502,993 | 54,380,947 | 53,665,143 | 53,789,674 | 53,426,163 | 53,330,837 | 53,099,330 | 53,187,764 | 53,005,344 | 52,927,467 | 52,615,269 | 52,658,850 | 52,557,035 | 52,534,787 | 52,412,181 | 52,453,384 | 52,385,590 | 52,336,443 | 52,227,630 | 51,919,894 | 51,536,474 | 51,046,375 | 50,530,968 | 50,158,634 | 49,516,595,000 | 49,427,825,000 | 49,240,099,000 | 48,515,071,000 | 47,911,932,000 | 44,563,299,000 | 42,900,269,000 | 42,056,285,000 | 16,817,841,000 | 1,676,442,000 | |||||
| diluted | 56,643,189 | 55,864,692 | 55,958,537 | 56,016,350 | 55,724,283 | 55,626,663 | 55,506,828 | 54,608,963 | 54,502,993 | 62,454,204 | 61,679,800 | 55,034,838 | 61,397,159 | 61,406,555 | 54,356,744 | 54,334,794 | 54,724,146 | 54,196,971 | 53,689,743 | 53,762,642 | 53,645,828 | 53,581,051 | 53,816,754 | 53,805,838 | 53,912,977 | 53,985,385 | 54,239,847 | 54,203,308 | 53,788,346 | 53,628,389 | 53,223,714 | 52,764,442 | 51,974,435,000 | 51,745,342,000 | 51,152,072,000 | 51,590,797,000 | 52,273,549,000 | 44,901,298,000 | 50,825,633,000 | 42,372,137,000 | 16,817,841,000 | 1,676,442,000 | |||||
| operating income | -10,256,000 | 22,342,000 | 26,067,000 | 16,788,000 | 19,839,000 | 10,440,000 | 5,318,000 | 4,309,000 | 3,076,000 | 3,430,000 | 29,167,000 | 3,756,000 | -17,175,000 | -15,479,000 | |||||||||||||||||||||||||||||||||
| yoy | 114.00% | 390.17% | 289.60% | 544.96% | 204.37% | -81.77% | 14.72% | -119.97% | -288.43% | ||||||||||||||||||||||||||||||||||||||
| qoq | -14.29% | 55.27% | -15.38% | 90.03% | 96.31% | 23.42% | 40.08% | -10.32% | -88.24% | 676.54% | 10.96% | ||||||||||||||||||||||||||||||||||||
| operating margin % | |||||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | 5,996,000 | 11,054,000 | 6,446,000 | -391,000 | 7,398,000 | 7,509,000 | 5,235,000 | 8,925,000 | 12,714,000 | 12,543,000 | 7,516,000 | 7,783,000 | 10,730,000 | 10,019,000 | 5,899,000 | 8,360,000 | 3,119,000 | 4,830,000 | 9,057,000 | 5,926,000 | 714,000 | 198,000 | 58,000 | 662,000 | 62,000 | ||||||||||||||||||||||
| interest expense | -910,000 | -1,505,000 | -1,594,000 | -1,724,000 | -1,810,000 | -1,942,000 | -5,934,000 | -5,925,000 | -5,467,000 | -6,097,000 | -6,096,000 | -6,088,000 | -5,815,000 | -5,755,000 | -2,870,000 | -2,144,000 | |||||||||||||||||||||||||||||||
| contingent consideration expense | -4,355,000 | -328,250 | -456,000 | 790,000 | 473,500 | 486,000 | 743,000 | 665,000 | -1,912,500 | 80,000 | 1,020,000 | ||||||||||||||||||||||||||||||||||||
| royalty and licensing revenues | 5,183,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| royalty revenues | 6,323,000 | 4,876,000 | 7,227,000 | 13,189,000 | 3,543,000 | 4,629,000 | 4,592,000 | 5,042,000 | 2,046,000 | 2,932,000 | 2,701,000 | 2,551,000 | 2,058,250 | 3,002,000 | 2,745,000 | 2,486,000 | 1,704,500 | 2,106,000 | 2,337,000 | 2,375,000 | |||||||||||||||||||||||||||
| contingent consideration (gain) expense | -1,647,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | -2,406,750 | -2,193,000 | 3,459,000 | -10,893,000 | |||||||||||||||||||||||||||||||||||||||||||
| interest income | 3,247,000 | 3,262,000 | 4,151,000 | 5,777,000 | 4,461,000 | 3,664,000 | 1,206,000 | 814,000 | 656,000 | 531,000 | 379,000 | 363,000 | 331,000 | 169,000 | 137,000 | 113,000 | 78,000 | 85,000 | 102,000 | 96,000 | 55,000 | 52,000 | 39,000 | 32,000 | 19,000 | ||||||||||||||||||||||
| licensing revenues | |||||||||||||||||||||||||||||||||||||||||||||||
| other income (expenses) | -295,000 | -139,000 | 148,000 | ||||||||||||||||||||||||||||||||||||||||||||
| cost of product sales | 4,044,000 | 3,684,000 | 4,207,000 | 3,683,000 | 3,278,000 | 4,251,000 | 3,861,000 | 2,949,000 | 3,428,000 | 2,751,000 | 2,035,000 | 2,248,000 | 1,762,000 | 1,618,000 | 1,321,000 | 1,661,000 | 494,000 | 33,000 | 4,000 | ||||||||||||||||||||||||||||
| other incomes | |||||||||||||||||||||||||||||||||||||||||||||||
| revenue | |||||||||||||||||||||||||||||||||||||||||||||||
| royalty revenue | 2,769,000 | 1,758,000 | 1,309,000 | 2,010,000 | 1,179,000 | 1,149,000 | 1,140,000 | ||||||||||||||||||||||||||||||||||||||||
| licensing revenue | 750,000 | 322,000 | 1,322,000 | 58,000 | 52,000 | 86,000 | 50,000 | 35,000 | 786,000 | 36,000 | 36,000 | 2,066,000 | 86,000 | 127,000 | 127,000 | ||||||||||||||||||||||||||||||||
| total revenue | 102,996,000 | 99,538,000 | 90,429,000 | 80,398,000 | 75,829,000 | 57,576,000 | 56,810,000 | 50,421,000 | 43,075,000 | 38,586,000 | 35,052,000 | 28,133,000 | 52,488,000 | 29,675,000 | 9,081,000 | 1,257,000 | 281,000 | ||||||||||||||||||||||||||||||
| interest expense-nonrecourse liability related to sale of future royalties | |||||||||||||||||||||||||||||||||||||||||||||||
| changes in fair value of derivative liabilities | 23,000 | 54,000 | 125,000 | 123,000 | 101,000 | 114,000 | 1,000 | 760,000 | 678,000 | 677,000 | -4,153,000 | -8,619,000 | |||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -1,162,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 0.4 | -0.21 | 0.28 | 0.7 | 0.36 | 0 | 0.02 | -0.29 | -0.02 | 0.31 | 0.47 | 0.03 | 0.15 | 0.48 | 0.05 | 0.41 | 0.45 | 0.11 | 0.58 | 0.76 | 0.66 | 0.41 | 0.63 | 0.55 | 0.62 | 0.35 | 0.54 | 0.59 | 0.51 | 0.31 | 0.34 | 0.21 | |||||||||||||||
| diluted | 0.4 | -0.21 | 0.27 | 0.69 | 0.36 | 0 | 0.02 | -0.29 | -0.02 | 0.29 | 0.42 | 0.03 | 0.14 | 0.43 | 0.04 | 0.4 | 0.43 | 0.11 | 0.57 | 0.74 | 0.65 | 0.4 | 0.62 | 0.54 | 0.61 | 0.34 | 0.52 | 0.57 | 0.49 | 0.29 | 0.32 | 0.19 | |||||||||||||||
| weighted-average number of common shares outstanding: | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 56,024,771 | 55,864,692 | 55,100,063 | 55,149,760 | 54,978,781 | 54,801,748 | 54,536,281 | 54,608,963 | 54,502,993 | 54,380,947 | 53,665,143 | 53,789,674 | 53,426,163 | 53,330,837 | 53,099,330 | 53,187,764 | 53,005,344 | 52,927,467 | 52,615,269 | 52,658,850 | 52,557,035 | 52,534,787 | 52,412,181 | 52,453,384 | 52,385,590 | 52,336,443 | 52,227,630 | 51,919,894 | 51,536,474 | 51,046,375 | 50,530,968 | 50,158,634 | 49,516,595,000 | 49,427,825,000 | 49,240,099,000 | 48,515,071,000 | 47,911,932,000 | 44,563,299,000 | 42,900,269,000 | 42,056,285,000 | 16,817,841,000 | 1,676,442,000 | |||||
| diluted | 56,643,189 | 55,864,692 | 55,958,537 | 56,016,350 | 55,724,283 | 55,626,663 | 55,506,828 | 54,608,963 | 54,502,993 | 62,454,204 | 61,679,800 | 55,034,838 | 61,397,159 | 61,406,555 | 54,356,744 | 54,334,794 | 54,724,146 | 54,196,971 | 53,689,743 | 53,762,642 | 53,645,828 | 53,581,051 | 53,816,754 | 53,805,838 | 53,912,977 | 53,985,385 | 54,239,847 | 54,203,308 | 53,788,346 | 53,628,389 | 53,223,714 | 52,764,442 | 51,974,435,000 | 51,745,342,000 | 51,152,072,000 | 51,590,797,000 | 52,273,549,000 | 44,901,298,000 | 50,825,633,000 | 42,372,137,000 | 16,817,841,000 | 1,676,442,000 | |||||
| weighted-average number of common shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 56,024,771 | 55,864,692 | 55,100,063 | 55,149,760 | 54,978,781 | 54,801,748 | 54,536,281 | 54,608,963 | 54,502,993 | 54,380,947 | 53,665,143 | 53,789,674 | 53,426,163 | 53,330,837 | 53,099,330 | 53,187,764 | 53,005,344 | 52,927,467 | 52,615,269 | 52,658,850 | 52,557,035 | 52,534,787 | 52,412,181 | 52,453,384 | 52,385,590 | 52,336,443 | 52,227,630 | 51,919,894 | 51,536,474 | 51,046,375 | 50,530,968 | 50,158,634 | 49,516,595,000 | 49,427,825,000 | 49,240,099,000 | 48,515,071,000 | 47,911,932,000 | 44,563,299,000 | 42,900,269,000 | 42,056,285,000 | 16,817,841,000 | 1,676,442,000 | |||||
| diluted | 56,643,189 | 55,864,692 | 55,958,537 | 56,016,350 | 55,724,283 | 55,626,663 | 55,506,828 | 54,608,963 | 54,502,993 | 62,454,204 | 61,679,800 | 55,034,838 | 61,397,159 | 61,406,555 | 54,356,744 | 54,334,794 | 54,724,146 | 54,196,971 | 53,689,743 | 53,762,642 | 53,645,828 | 53,581,051 | 53,816,754 | 53,805,838 | 53,912,977 | 53,985,385 | 54,239,847 | 54,203,308 | 53,788,346 | 53,628,389 | 53,223,714 | 52,764,442 | 51,974,435,000 | 51,745,342,000 | 51,152,072,000 | 51,590,797,000 | 52,273,549,000 | 44,901,298,000 | 50,825,633,000 | 42,372,137,000 | 16,817,841,000 | 1,676,442,000 | |||||
| net income | 15,961,000 | 17,368,000 | 10,297,000 | 61,826,000 | 10,018,000 | 4,987,000 | 4,222,000 | 2,005,000 | 917,000 | 27,858,000 | 3,202,000 | -15,543,000 | -24,096,000 | -27,357,000 | -13,482,000 | -9,277,000 | |||||||||||||||||||||||||||||||
| yoy | 59.32% | 248.27% | 143.89% | 2983.59% | 992.48% | -82.10% | 31.86% | -112.90% | -103.81% | -201.83% | 15.29% | 194.89% | |||||||||||||||||||||||||||||||||||
| qoq | -8.10% | 68.67% | -83.35% | 517.15% | 100.88% | 18.12% | 110.57% | 118.65% | -96.71% | 770.02% | -120.60% | -35.50% | -11.92% | ||||||||||||||||||||||||||||||||||
| net income margin % | |||||||||||||||||||||||||||||||||||||||||||||||
| interest expense-non-recourse royalty liability | |||||||||||||||||||||||||||||||||||||||||||||||
| income per common share: | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 1,250 | 200 | 100 | 90 | 40 | 20 | 650 | 80 | |||||||||||||||||||||||||||||||||||||||
| diluted | 1,180 | 180 | 80 | 80 | 30 | 20 | 390 | 80 | |||||||||||||||||||||||||||||||||||||||
| revenue from royalty agreement | 30,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares: | |||||||||||||||||||||||||||||||||||||||||||||||
| basic | 56,024,771 | 55,864,692 | 55,100,063 | 55,149,760 | 54,978,781 | 54,801,748 | 54,536,281 | 54,608,963 | 54,502,993 | 54,380,947 | 53,665,143 | 53,789,674 | 53,426,163 | 53,330,837 | 53,099,330 | 53,187,764 | 53,005,344 | 52,927,467 | 52,615,269 | 52,658,850 | 52,557,035 | 52,534,787 | 52,412,181 | 52,453,384 | 52,385,590 | 52,336,443 | 52,227,630 | 51,919,894 | 51,536,474 | 51,046,375 | 50,530,968 | 50,158,634 | 49,516,595,000 | 49,427,825,000 | 49,240,099,000 | 48,515,071,000 | 47,911,932,000 | 44,563,299,000 | 42,900,269,000 | 42,056,285,000 | 16,817,841,000 | 1,676,442,000 | |||||
| diluted | 56,643,189 | 55,864,692 | 55,958,537 | 56,016,350 | 55,724,283 | 55,626,663 | 55,506,828 | 54,608,963 | 54,502,993 | 62,454,204 | 61,679,800 | 55,034,838 | 61,397,159 | 61,406,555 | 54,356,744 | 54,334,794 | 54,724,146 | 54,196,971 | 53,689,743 | 53,762,642 | 53,645,828 | 53,581,051 | 53,816,754 | 53,805,838 | 53,912,977 | 53,985,385 | 54,239,847 | 54,203,308 | 53,788,346 | 53,628,389 | 53,223,714 | 52,764,442 | 51,974,435,000 | 51,745,342,000 | 51,152,072,000 | 51,590,797,000 | 52,273,549,000 | 44,901,298,000 | 50,825,633,000 | 42,372,137,000 | 16,817,841,000 | 1,676,442,000 | |||||
| loss per common share: | |||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -380 | -780 | -890 | -600 | |||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares: | |||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 41,129,055,000 | 30,941,404,000 | 30,897,075,000 | 30,875,424,000 | 24,464,281,000 | ||||||||||||||||||||||||||||||||||||||||||
| cumulative dividends on series a | |||||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -24,096,000 | -27,357,000 | -18,414,000 | -13,482,000 | -10,135,000 | ||||||||||||||||||||||||||||||||||||||||||
| cumulative dividends on series a convertible preferred stock | -858,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||||||||||||||||||||
| operating income from continuing operations | |||||||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations | |||||||||||||||||||||||||||||||||||||||||||||||
| discontinued operations: | |||||||||||||||||||||||||||||||||||||||||||||||
| income from discontinued operations | |||||||||||||||||||||||||||||||||||||||||||||||
| continuing operations | -550 | -6,050 | |||||||||||||||||||||||||||||||||||||||||||||
| discontinued operations | |||||||||||||||||||||||||||||||||||||||||||||||
| development and milestone revenues | 91,000 | 208,000 | |||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 2,728,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| other |
We provide you with 20 years income statements for Supernus Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Supernus Pharmaceuticals stock. Explore the full financial landscape of Supernus Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Supernus Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.